62,691 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by Cerity Partners LLC

Cerity Partners LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 62,691 shares of the company’s stock, valued at approximately $332,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares during the period. NewEdge Advisors LLC raised its position in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after acquiring an additional 2,387 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth $54,000. San Luis Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth $54,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth $67,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $7.00.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $6.49 on Monday. The firm’s 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.96. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The firm has a market capitalization of $2.64 billion, a PE ratio of -3.67 and a beta of 0.91. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the business earned ($0.39) EPS. The business’s revenue was up 7.2% on a year-over-year basis. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.